CTMX vs CUBE · rev $138.1M vs P/E 25, rev $1.07B
CytomX Therapeutics Inc (CTMX) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported CTMX revenue for 2024-12-31 was $138.1M. Net income was $31.9M. Revenue was up 36.4% from 2023-12-31 to 2024-12-31. CTMX currently screens at market cap $653.1M.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
CTMX currently screens at market cap $653.1M. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the CTMX and CUBE stock pages for the full models.
Not investment advice.